WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- Four in every 10 cancer patients treated with chemotherapy develop severe ...

The pooled prevalence of chronic painful neuropathy is 41.22% among individuals with chemotherapy-induced peripheral neuropathy (CIPN).

Four in 10 patients treated with chemotherapy experience persistent severe peripheral nerve pain, a recent study found. The study, published in Regional Anesthesia & Pain Medicine, analyzed data ...

Managing maximum tolerated dose (MTD) chemotherapy while minimizing neutropenia relies on precise complete blood count (CBC) monitoring and AI-powered diagnostics.

Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

San Antonio teamed up with Angeles Sin Fronteras to provide free wigs and cosmetic kits to local cancer patients undergoing ...

The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term ...

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed ...

A recent survey revealed that many patients were worried about the physical effects of radiation, and more than one third ...

Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.